2.25
Century Therapeutics Inc stock is traded at $2.25, with a volume of 910.56K.
It is down -0.44% in the last 24 hours and down -18.77% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$2.26
Open:
$2.26
24h Volume:
910.56K
Relative Volume:
0.50
Market Cap:
$404.38M
Revenue:
$109.16M
Net Income/Loss:
$-9.57M
P/E Ratio:
-21.39
EPS:
-0.1052
Net Cash Flow:
$-104.72M
1W Performance:
+5.63%
1M Performance:
-18.77%
6M Performance:
+295.64%
1Y Performance:
+451.74%
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IPSC
Century Therapeutics Inc
|
2.25 | 404.38M | 109.16M | -9.57M | -104.72M | -0.1052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics (IPSC) awards 88,000 stock options to new director - Stock Titan
Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 - Stock Titan
CEO Moves: Will Century Therapeutics Inc benefit from current market trendsQuarterly Market Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Action: Is Century Therapeutics Inc undervalued by DCF analysisTake Profit & Expert Curated Trade Setups - baoquankhu1.vn
Panic Selling: What are the future prospects of Century Therapeutics IncBear Alert & Verified Momentum Watchlists - baoquankhu1.vn
Century Therapeutics (NASDAQ: IPSC) CSO has shares withheld for taxes - Stock Titan
IPSC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Options Flow: What are the future prospects of Century Therapeutics IncQuarterly Profit Summary & Smart Money Movement Tracker - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update - MarketBeat
VIX Spike: How does Century Therapeutics Inc perform in inflationary periods2026 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Century Therapeutics Updates ATM Program to Enhance Liquidity - TipRanks
Century Therapeutics updates equity offering program with $131.6 million remaining - Investing.com Australia
Century Therapeutics (IPSC) files $150M ATM shelf with TD Cowen - Stock Titan
Century Therapeutics (NASDAQ: IPSC) refreshes shelf and $150,000,000 ATM stock program - Stock Titan
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - MSN
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Century Therapeutics, Inc. has successfully sold common stock worth $18.4 million through investment bank TD Cowen. - Bitget
Weekly Trades: Is Century Therapeutics Inc in a bullish channel2026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Downgrade Watch: Will Century Therapeutics Inc benefit from seasonality2026 Dividend Review & Breakout Confirmation Alerts - baoquankhu1.vn
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Century Therapeutics reports 2025 results, advances cell therapy pipeline - MSN
Fed Meeting: Will Arch Capital Group Ltd outperform small cap indexes2026 Buyback Activity & Real-Time Volume Surge Alerts - baoquankhu1.vn
Dip Buying: How sensitive is Century Therapeutics Inc to inflationQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline - MyChesCo
Century Therapeutics Hits New 52-Week High at $2.95 - Markets Mojo
Century Therapeutics Hits New 52-Week High of $3.04 Amid Market Fluctuations - Markets Mojo
Century Therapeutics (NASDAQ:IPSC) Insider Sells $25,693.80 in Stock - MarketBeat
Century Therapeutics (NASDAQ:IPSC) SVP Sells $17,959.65 in Stock - MarketBeat
Century Therapeutics (IPSC) SVP sells 7,043 shares to cover tax withholding - stocktitan.net
Century Therapeutics (IPSC) officer sells shares to cover tax - stocktitan.net
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Zacks Research Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
Century Therapeutics (IPSC) CEO has 55,397 shares withheld for RSU taxes - Stock Titan
Century Therapeutics (IPSC) CSO has 1,431 shares withheld for RSU tax obligations - Stock Titan
Century Therapeutics (IPSC) Receives a Buy from Clear Street - The Globe and Mail
Century Therapeutics (NASDAQ:IPSC) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Lantheus (LNTH), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives - simplywall.st
IPSC (NASDAQ: IPSC) plans sale of 10,076 vested shares via Fidelity - Stock Titan
Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors - marketscreener.com
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Century Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Century Therapeutics Reports 2025 Results and Pipeline Progress - TipRanks
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates - Investing News Network
CENTURY THERAPEUTICS ($IPSC) Releases Q4 2025 Earnings - Quiver Quantitative
Century Therapeutics 10-K Summary — Revenue: $— | EPS: $— - TradingView
Century Therapeutics 2025 net loss narrows beating estimates - TradingView
Century Therapeutics (NASDAQ: IPSC) slashes 2025 net loss on $109M revenue - Stock Titan
BRIEF-Century Therapeutics FY Net Income USD -9.58 Million - TradingView
Bearish Setup: Is Century Therapeutics Inc undervalued by DCF analysis2026 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) officer auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russotti Gregory | See Remarks |
Mar 12 '26 |
Sale |
2.55 |
10,076 |
25,684 |
515,427 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):